Home Patent Forecast® Sectors Log In   Sign Up   Free Trial   Support   Contact   Pricing  
How it works Patent Forecast® Sectors Pricing Insights
Menu

Injectable Cannabis Formulations from GW Pharma

Z-ARCHIVE-Cannabis Patent Forecast®

October 24, 2019

GW Pharmaceuticals is experimenting with an intravenous cannabinoid formulation for treating “conditions requiring the administration of a neuroprotectant or anti-convulsive medication” (US Publication 20190314296). The IV formulation contains a cannabinoid in the concentration of 0.3 mg/ml to 50 mg/ml. For comparison, their CBD extract medication Epidiolex has a concentration of 100 mg/ml, however, it is taken orally. As expected, uses for cancer treatments are also described in the patent application. GW has completed Phase I trials for the IV formulation in patients with Neonatal Hypoxic-Ischemic Encephalopathy (NHIE) and will consult with the FDA soon to come up with safe and efficacious study designs.   

Checklist, Clinic, Daily Report, Diagnosis, Doctor

Relevant Patent Documents

Application US20190314296  

Article Source Link

GW Pharma


Z-ARCHIVE-Cannabis   Patent Forecast®

View Patent Forecast® Top Corporations News and Insights Data Visualization

For a blog.



301